Enhanced secretion of glucagon-like peptide 1 by biguanide compounds.

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Biochemical and Biophysical Research Communications - BBRC

• Publication date

  2002-11-15

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/S0006-291X(02)02565-2PMID 12419322
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The insulinotropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to type 2 diabetes.

  2002cited by this paper
• Improvement of high fat-diet-induced insulin resistance in dipeptidyl peptidase IV-deficient Fischer rats.

  2002cited by this paper
• Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes.

  2002cited by this paper
• Dipeptidyl peptidase IV inhibition as an approach to the treatment and prevention of type 2 diabetes: a historical perspective.

  2002cited by this paper
• Rebuttal to Deacon and Holst: "Metformin effects on dipeptidyl peptidase IV degradation of glucagon-like peptide-1" versus "Dipeptidyl peptidase inhibition as an approach to the treatment and prevention of type 2 diabetes: a historical perspective".

  2002cited by this paper
• Metformin effects on dipeptidylpeptidase IV degradation of glucagon-like peptide-1.

  2002cited by this paper
• On combination therapy of diabetes with metformin and dipeptidyl peptidase IV inhibitors.

  2002cited by this paper
• Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study.

  2002cited by this paper
• Glucagon-like peptide-1.

  2001cited by this paper
• Additive glucose-lowering effects of glucagon-like peptide-1 and metformin in type 2 diabetes.

  2001cited by this paper
• Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects.

  2001influential reference
• Improved glucose tolerance via enhanced glucose-dependent insulin secretion in dipeptidyl peptidase IV-deficient Fischer rats.

  2001cited by this paper
• Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice.

  2000cited by this paper
• The antihyperglycaemic effect of metformin: therapeutic and cellular mechanisms.

  1999cited by this paper
• Glucagon-like peptide-1, a gastrointestinal hormone with a pharmaceutical potential.

  1999cited by this paper
• Glucagon-Like Peptides

  1998cited by this paper
• Enteroglucagon.

  1997cited by this paper
• Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal.

  1994cited by this paper
• Subcutaneous Injection of the Incretin Hormone Glucagon-Like Peptide 1 Abolishes Postprandial Glycemia in NIDDM

  1994cited by this paper
• Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in Type 2 (non-insulin-dependent) diabetic patients

  1993cited by this paper
• Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus.

  1992cited by this paper
• Glucose-dependency of the insulin stimulatory effect of glucagon-like peptide-1 (7–36) amide on the rat pancreas

  1992cited by this paper
• Biguanides and NIDDM

  1992cited by this paper

• Metformin Beyond Glycemic Control: Cardiovascular Protection and Diabetes Prevention

  2026cites this paper
• Overview of Metformin and Neurodegeneration: A Comprehensive Review

  2025cites this paper
• Pancreastatin inhibitor PSTi8 alleviates insulin resistance and ovarian dysfunction in a dehydroepiandrosterone-high-fat diet rat model of polycystic ovary syndrome.

  2025cites this paper
• Understanding the action mechanisms of metformin in the gastrointestinal tract

  2024cites this paper
• Metformin reduces insulin resistance and attenuates progressive renal injury in prepubertal obese Dahl salt-sensitive rats.

  2023cites this paper
• Focus on Metformin: Its Role and Safety in Pregnancy and Beyond

  2023cites this paper
• Therapeutic Potential of Glucagon-like Peptide-1 Agonists in Polycystic Ovary Syndrome: From Current Clinical Evidence to Future Perspectives

  2022cites this paper
• Remission of Type 2 Diabetes Following a Short-term Intensive Intervention With Insulin Glargine, Sitagliptin, and Metformin: Results of an Open-label Randomized Parallel-Design Trial.

  2021cites this paper
• Biguanides drugs: Past success stories and promising future for drug discovery.

  2021cites this paper
• Evaluating the Evidence behind the Novel Strategy of Early Combination from Vision to Implementation

  2020cites this paper
• Intestine-selective reduction of Gcg expression reveals the importance of the distal gut for GLP-1 secretion

  2020cites this paper
• Remission of type 2 diabetes following a short-term intervention with insulin glargine, metformin and dapagliflozin.

  2020cites this paper
• Dipeptidyl Peptidase-4 at the Interface Between Inflammation and Metabolism

  2020cites this paper
• Physiology of the Incretin Hormones, GIP and GLP-1-Regulation of Release and Posttranslational Modifications.

  2019cites this paper
• Genistein enhances the secretion of glucagon-like peptide-1 (GLP-1) via downregulation of inflammatory responses.

  2019cites this paper
• Disparities in the Efficacy of Metformin in Combination with Dipeptidyl Peptidase-4 Inhibitor as Initial Treatment Stratified by Dosage and Ethnicity: A Meta-Analysis

  2018influential citation
• Metformin and β‐cell function in insulin‐treated patients with type 2 diabetes: A randomized placebo‐controlled 4.3‐year trial

  2018cites this paper
• THE IMPACT OF DEGRADATION INHIBITOR OF GLUCAGON LIKE POLYPEPTIDE 1 ON BODY WEIGHT AND BETA-CELL FUNCTION IN OBESE WOMEN WITH POLYCYSTIC OVARIAN SYNDROME

  2018cites this paper
• Have dipeptidyl peptidase-4 inhibitors ameliorated the vascular complications of type 2 diabetes in large-scale trials? The potential confounding effect of stem-cell chemokines

  2018cites this paper
• The role of neuropeptide Y in the pathogenesis of the metabolic syndrome : A study of liver metabolism in transgenic mice overexpressing neuropeptide Y in noradrenergic neurons

  2018cites this paper
• Incretin System: New Pharmacological Target in Obese Women with Polycystic Ovary Syndrome

  2018cites this paper
• Metformin normalizes the structural changes in glycogen preceding prediabetes in mice overexpressing neuropeptide Y in noradrenergic neurons

  2018cites this paper
• Metformin in gestational diabetes mellitus

  2017cites this paper
• Short-term effectiveness of low dose liraglutide in combination with metformin versus high dose liraglutide alone in treatment of obese PCOS: randomized trial

  2017influential citation
• Potential New Pharmacological Approaches in Obese Women with Polycystic Ovary Syndrome

  2017cites this paper
• GLP-1 Receptor Agonists for the Treatment of Diabetes and Obesity

  2017cites this paper
• DPP4 INHIBITOR SITAGLIPTIN AS A POTENTIAL TREATMENT OPTION IN METFORMIN-INTOLERANT OBESE WOMEN WITH POLYCYSTIC OVARY SYNDROME: A PILOT RANDOMIZED STUDY.

  2017cites this paper
• Differential increments of basal glucagon‐like‐1 peptide concentration among SLC47A1 rs2289669 genotypes were associated with inter‐individual variability in glycaemic response to metformin in Chinese people with newly diagnosed Type 2 diabetes

  2017cites this paper
• Metformin ameliorates diabetes with metabolic syndrome induced changes in experimental rats

  2016cites this paper
• Involvement of glucagon‐like peptide‐1 in the glucose‐lowering effect of metformin

  2016cites this paper
• Metformin as an initial adjunct to low-dose liraglutide enhances the weight-decreasing potential of liraglutide in obese polycystic ovary syndrome: Randomized control study

  2016cites this paper
• Abundance and turnover of GLP-1 producing L-cells in ileal mucosa are not different in patients with and without type 2 diabetes.

  2016cites this paper
• Proglucagon Promoter Cre-Mediated AMPK Deletion in Mice Increases Circulating GLP-1 Levels and Oral Glucose Tolerance

  2016influential citation
• Unravelling the immunological roles of dipeptidyl peptidase 4 (DPP4) activity and/or structure homologue (DASH) proteins

  2016cites this paper
• Changes in glucose-induced plasma active glucagon-like peptide-1 levels by co-administration of sodium-glucose cotransporter inhibitors with dipeptidyl peptidase-4 inhibitors in rodents.

  2016cites this paper
• Efficacy and safety of initial combination therapy with gemigliptin and metformin compared with monotherapy with either drug in patients with type 2 diabetes: A double‐blind randomized controlled trial (INICOM study)

  2016cites this paper
• Metformin and the gastrointestinal tract

  2016cites this paper
• Add-on therapy with anagliptin in Japanese patients with type-2 diabetes mellitus treated with metformin and miglitol can maintain higher concentrations of biologically active GLP-1/total GIP and a lower concentration of leptin.

  2016cites this paper
• Combination therapy in type 2 diabetes mellitus

  2015cites this paper
• The Primary Glucose-Lowering Effect of Metformin Resides in the Gut, Not the Circulation: Results From Short-term Pharmacokinetic and 12-Week Dose-Ranging Studies

  2015cites this paper
• GLP-1 secretagogues potential of medicinal plants in management of diabetes

  2015cites this paper
• Molecular action of metformin in hepatocytes: an updated insight.

  2015cites this paper
• Combination therapy of dipeptidyl peptidase‐4 inhibitors and metformin in type 2 diabetes: rationale and evidence

  2014cites this paper
• The Cardiovascular Effects of Metformin: Conventional and New Insights

  2014cites this paper
• Metformin—mode of action and clinical implications for diabetes and cancer

  2014cites this paper
• Efficacy of Combination Therapy With Sitagliptin and Low-Dose Glimepiride in Japanese Patients With Type 2 Diabetes

  2014cites this paper
• Gut Hormone Pharmacology of a Novel GPR119 Agonist (GSK1292263), Metformin, and Sitagliptin in Type 2 Diabetes Mellitus: Results from Two Randomized Studies

  2014cites this paper
• Pharmacology of the GLP-1 Analog Liraglutide in Healthy Cats

  2014cites this paper
• Synergism in Combined Use of Oral Antihyperglycemic Drugs

  2014cites this paper
• Синергизм при комбинированном иСпользовании пероральных СахароСнижающих препаратов

  2014cites this paper
• Enteral Nutrition and Glucagon-Like Peptide-1 in Intensive Care Unit Patients

  2014cites this paper
• Metformin enhances glucagon-like peptide 1 via cooperation between insulin and Wnt signaling.

  2014cites this paper
• The ‘collateral benefits‘ of noninsulin therapies for Type 2 diabetes

  2013cites this paper
• Physiology of incretins and loss of incretin effect in type 2 diabetes and obesity

  2013influential citation
• Profile of vildagliptin in type 2 diabetes: efficacy, safety, and patient acceptability

  2013cites this paper
• Safety and Efficacy of Sitagliptin-Metformin in Fixed Combination for the Treatment of Type 2 Diabetes Mellitus

  2013cites this paper
• AMPK Is Involved in the Regulation of Incretin Receptors Expression in Pancreatic Islets under a Low Glucose Concentration

  2013cites this paper
• Effects of aerobic exercise with or without metformin on plasma incretins in type 2 diabetes.

  2013cites this paper
• Pathophysiologic Approach to Therapy in Patients With Newly Diagnosed Type 2 Diabetes

  2013cites this paper
• Predictive factors of durability to sitagliptin: Slower reduction of glycated hemoglobin, older age and higher baseline glycated hemoglobin

  2013cites this paper
• ApproachtoTherap y in Patients With Newly Diagnosed Type 2 Diabetes

  2013cites this paper
• Emerging Concepts in Metformin Therapy: Hyperglycaemia and Beyond

  2013cites this paper
• The Effect of Alogliptin and Metformin Combination Therapy in Type 2 Diabetes: A Pilot Study

  2013influential citation
• [Preclinical and clinical aspects of the dipeptidyl peptidase-4 inhibitor anagliptin].

  2013cites this paper
• A simultaneous assay method using capillary zone electrophoresis for a fixed dose combination of vildagliptin and metformin hydrochloride in coated tablets

  2013cites this paper
• Efficacy and safety of combination therapy with vildagliptin and metformin versus metformin up-titration in Chinese patients with type 2 diabetes mellitus: study design and rationale of the vision study

  2013cites this paper
• Emerging diabetes therapies and technologies.

  2012cites this paper
• Molecular regulation of hormone secretion, growth and apoptosis of GLP-1-producing cells

  2012cites this paper
• The Effect of Adding Sitagliptin on Improving Glycemic Control in Combination with Multiple Antidiabetic Agents

  2012cites this paper
• Factors predicting therapeutic efficacy of combination treatment with sitagliptin and metformin in type 2 diabetic patients: the COSMETIC study

  2012cites this paper
• Prebiotic fiber increases hepatic acetyl CoA carboxylase phosphorylation and suppresses glucose-dependent insulinotropic polypeptide secretion more effectively when used with metformin in obese rats.

  2012cites this paper
• DIABETIC STUDIES The Review of Physiology of Incretins in Health and Disease

  2012cites this paper
• Recommendations for diagnosis and management of metformin-induced vitamin B12 (Cbl) deficiency.

  2012cites this paper
• Adding saxagliptin to extended‐release metformin vs. uptitrating metformin dosage

  2012cites this paper
• Effects of chronic treatment with metformin on dipeptidyl peptidase‐4 activity, glucagon‐like peptide 1 and ghrelin in obese patients with Type 2 diabetes mellitus

  2012cites this paper
• Novel biological action of the dipeptidylpeptidase-IV inhibitor, sitagliptin, as a glucagon-like peptide-1 secretagogue.

  2012cites this paper
• Different modulation of dipeptidyl peptidase-4 activity between microvascular and macrovascular human endothelial cells

  2012cites this paper
• DPP IV inhibitors: successes, failures and future prospects.

  2011cites this paper
• New aspects of an old drug: metformin as a glucagon-like peptide 1 (GLP-1) enhancer and sensitiser

  2011cites this paper
• A Dose-Ranging Study of the DPP-IV Inhibitor PF-734200 Added to Metformin in Subjects With Type 2 Diabetes*.

  2011cites this paper
• Impact of Diabetes and its pharmacological treatment on cardiovascular function: studies on ischaemia-reperfusion models

  2011cites this paper
• Incretin secretion is not restored by short-term strict glycaemic control in Korean hyperglycaemic patients with type 2 diabetes.

  2011cites this paper
• Sitagliptin and metformin combination therapy for the treatment of Type 2 diabetes

  2011cites this paper
• Metformin is the lifelong partner in diabetes management: true or false? A report from a symposium held on the occasion of the 46th Annual Meeting of the EASD, Stockholm, 20-24 September, 2010

  2011cites this paper
• Resveratrol Increases Glucose Induced GLP-1 Secretion in Mice: A Mechanism which Contributes to the Glycemic Control

  2011cites this paper
• Loss of Incretin Effect Is a Specific, Important, and Early Characteristic of Type 2 Diabetes

  2011cites this paper
• Mechanisms underlying metformin-induced secretion of glucagon-like peptide-1 from the intestinal L cell.

  2011influential citation
• Clinical evidence and mechanistic basis for vildagliptin's action when added to metformin

  2011cites this paper
• Screening for and Management of Obesity and Overweight in Adults

  2011cites this paper
• Combination of TS-021 with metformin improves hyperglycemia and synergistically increases pancreatic β-cell mass in a mouse model of type 2 diabetes.

  2011cites this paper
• Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-α in mice

  2011influential citation
• Physiology of incretins in health and disease.

  2011cites this paper
• Efficacy and safety of saxagliptin added to metformin in Asian people with type 2 diabetes mellitus: a randomized controlled trial.

  2011cites this paper
• Dipeptidyl Peptidase‐4 Inhibitors Administered in Combination With Metformin Result in an Additive Increase in the Plasma Concentration of Active GLP‐1

  2010cites this paper
• The gut-brain axis: a major glucoregulatory player.

  2010cites this paper
• Comparative effects of telmisartan, sitagliptin and metformin alone or in combination on obesity, insulin resistance, and liver and pancreas remodelling in C57BL/6 mice fed on a very high-fat diet.

  2010cites this paper
• Is the Diminished Incretin Effect in Type 2 Diabetes Just an Epi-Phenomenon of Impaired β-Cell Function?

  2010cites this paper
• Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?

  2010cites this paper
• Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes following myocardial infarction in mice

  2010cites this paper
• Incretin hormone secretion over the day.

  2010cites this paper